Latest SILVERARC CAPITAL MANAGEMENT, LLC Stock Portfolio
SILVERARC CAPITAL MANAGEMENT, LLC Performance:
2025 Q3: 16.1%YTD: 24.92%2024: 14.9%
Performance for 2025 Q3 is 16.1%, and YTD is 24.92%, and 2024 is 14.9%.
About SILVERARC CAPITAL MANAGEMENT, LLC and 13F Hedge Fund Stock Holdings
SILVERARC CAPITAL MANAGEMENT, LLC is a hedge fund based in BOSTON, MA. On 24-Mar-2023, the fund reported that it had an AUM (Regulated Assets under Management) of $441.6 Millions. In it's latest 13F Holdings report, SILVERARC CAPITAL MANAGEMENT, LLC reported an equity portfolio of $741.6 Millions as of 30 Sep, 2025.
The top stock holdings of SILVERARC CAPITAL MANAGEMENT, LLC are , RYTM, RNA. The fund has invested 6.2% of it's portfolio in ABIVAX SA and 5% of portfolio in RHYTHM PHARMACEUTICALS INC.
The fund managers got completely rid off MERUS N V (MRUS), VERONA PHARMA PLC (VRNA) and NEUROCRINE BIOSCIENCES INC (NBIX) stocks. They significantly reduced their stock positions in MOONLAKE IMMUNOTHERAPEUTICS (MLTX), VERACYTE INC (VCYT) and ERASCA INC (ERAS). SILVERARC CAPITAL MANAGEMENT, LLC opened new stock positions in ABIVAX SA, COGENT BIOSCIENCES INC (COGT) and CYTOKINETICS INC (CYTK). The fund showed a lot of confidence in some stocks as they added substantially to FRACTYL HEALTH INC, CENTESSA PHARMACEUTICALS PLC (CNTA) and PRAXIS PRECISION MEDICINES I (PRAX).
The top stock holdings of SILVERARC CAPITAL MANAGEMENT, LLC are , RYTM, RNA. The fund has invested 6.2% of it's portfolio in ABIVAX SA and 5% of portfolio in RHYTHM PHARMACEUTICALS INC.
The fund managers got completely rid off MERUS N V (MRUS), VERONA PHARMA PLC (VRNA) and NEUROCRINE BIOSCIENCES INC (NBIX) stocks. They significantly reduced their stock positions in MOONLAKE IMMUNOTHERAPEUTICS (MLTX), VERACYTE INC (VCYT) and ERASCA INC (ERAS). SILVERARC CAPITAL MANAGEMENT, LLC opened new stock positions in ABIVAX SA, COGENT BIOSCIENCES INC (COGT) and CYTOKINETICS INC (CYTK). The fund showed a lot of confidence in some stocks as they added substantially to FRACTYL HEALTH INC, CENTESSA PHARMACEUTICALS PLC (CNTA) and PRAXIS PRECISION MEDICINES I (PRAX).
SILVERARC CAPITAL MANAGEMENT, LLC Annual Return Estimates Vs S&P 500
Our best estimate is that SILVERARC CAPITAL MANAGEMENT, LLC made a return of 16.1% in the last quarter. In trailing 12 months, it's portfolio return was 24.13%.
New Buys
| Ticker | $ Bought |
|---|---|
| abivax sa | 45,820,900 |
| cogent biosciences inc | 11,704,500 |
| cytokinetics inc | 11,596,600 |
| biogen inc | 11,265,100 |
| amylyx pharmaceuticals inc | 9,513,000 |
| verastem inc | 9,207,540 |
| avalo therapeutics inc | 9,162,920 |
| olema pharmaceuticals inc | 9,139,370 |
New stocks bought by SILVERARC CAPITAL MANAGEMENT, LLC
Additions
| Ticker | % Inc. |
|---|---|
| fractyl health inc | 5,132 |
| centessa pharmaceuticals plc | 2,724 |
| dianthus therapeutics inc | 604 |
| praxis precision medicines i | 412 |
| kodiak sciences inc | 149 |
| compass therapeutics inc | 126 |
| uniqure nv | 124 |
| cidara therapeutics inc | 112 |
Additions to existing portfolio by SILVERARC CAPITAL MANAGEMENT, LLC
Reductions
| Ticker | % Reduced |
|---|---|
| moonlake immunotherapeutics | -63.42 |
| veracyte inc | -47.43 |
| erasca inc | -46.76 |
| sionna therapeutics inc | -41.51 |
| ascendis pharma a/s | -38.13 |
| scholar rock hldg corp | -31.4 |
| mineralys therapeutics inc | -30.6 |
| kalvista pharmaceuticals inc | -25.59 |
SILVERARC CAPITAL MANAGEMENT, LLC reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| 89bio inc | -20,004,200 |
| merus n v | -39,027,700 |
| helix acquisition corp ii | -6,514,230 |
| verona pharma plc | -33,887,700 |
| pfizer inc | -8,346,750 |
| metsera inc | -5,905,680 |
| soleno therapeutics inc | -17,140,600 |
| structure therapeutics inc | -3,642,690 |
SILVERARC CAPITAL MANAGEMENT, LLC got rid off the above stocks
Sector Distribution
SILVERARC CAPITAL MANAGEMENT, LLC has about 73.7% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 73.7 |
| Others | 26.3 |
Market Cap. Distribution
SILVERARC CAPITAL MANAGEMENT, LLC has about 5.9% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| SMALL-CAP | 29.6 |
| UNALLOCATED | 25.9 |
| MID-CAP | 21.4 |
| MICRO-CAP | 15.4 |
| LARGE-CAP | 5.9 |
| NANO-CAP | 1.8 |
Stocks belong to which Index?
About 59% of the stocks held by SILVERARC CAPITAL MANAGEMENT, LLC either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| RUSSELL 2000 | 57.4 |
| Others | 41 |
| S&P 500 | 1.6 |
SILVERARC CAPITAL MANAGEMENT, LLC Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of SILVERARC CAPITAL MANAGEMENT, LLC
SILVERARC CAPITAL MANAGEMENT, LLC has 73 stocks in it's portfolio. About 43.5% of the portfolio is in top 10 stocks. AKRO proved to be the most loss making stock for the portfolio. RYTM was the most profitable stock for SILVERARC CAPITAL MANAGEMENT, LLC last quarter.
Last Reported on: 12 Nov, 2025| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ABEO | abeona therapeutics inc | 0.71 | 994,754 | 5,252,300 | added | 8.37 | ||
| AKRO | akero therapeutics inc | 4.12 | 643,636 | 30,559,800 | reduced | -9.83 | ||
| ALKS | alkermes plc | 0.73 | 180,513 | 5,415,390 | new | |||
| AMLX | amylyx pharmaceuticals inc | 1.28 | 700,000 | 9,513,000 | new | |||
| ARCT | arcturus therapeutics hldgs | 0.01 | 3,445 | 63,491 | new | |||
| AVTX | avalo therapeutics inc | 1.24 | 720,922 | 9,162,920 | new | |||
| AZYO | elutia inc | 0.34 | 2,850,990 | 2,537,950 | added | 3.23 | ||
| BDSX | biodesix inc | 0.05 | 49,607 | 374,533 | new | |||
| BDSX | biodesix inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| BIIB | biogen inc | 1.52 | 80,419 | 11,265,100 | new | |||
| BNTC | benitec biopharma inc | 0.52 | 276,267 | 3,876,030 | added | 9.1 | ||
| CCCC | c4 therapeutics inc | 0.57 | 1,897,380 | 4,212,190 | new | |||
| CDTX | cidara therapeutics inc | 2.85 | 220,902 | 21,153,600 | added | 112 | ||
| CELC | celcuity inc | 0.59 | 88,686 | 4,381,090 | new | |||
| CERS | cerus corp | 0.58 | 2,715,790 | 4,318,100 | added | 9.14 | ||
| CLDX | celldex therapeutics inc new | 1.22 | 348,922 | 9,026,610 | added | 75.83 | ||
| CMPX | compass therapeutics inc | 1.34 | 2,833,990 | 9,918,960 | added | 126 | ||
| CNTA | centessa pharmaceuticals plc | 0.46 | 141,238 | 3,425,020 | added | 2,724 | ||
| COGT | cogent biosciences inc | 1.58 | 815,075 | 11,704,500 | new | |||
| CRNX | crinetics pharmaceuticals in | 0.28 | 50,000 | 2,082,500 | new | |||